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Background:  Visfatin is an adipokine produced by visceral adipose tissue and has insulin-mimicking effects. Fetuin-A is a he-
patic secretory protein that binds the insulin receptor and inhibits insulin action both in vivo and in vitro. The authors of the 
present study aimed to investigate the levels of serum visfatin and fetuin-A and their correlation with hemoglobin A1c (HbA1c) 
and urine albumin levels in patients with type 2 diabetes mellitus (T2DM).
Methods:  A total of 40 obese patients with T2DM (11 males and 29 females; age, 54.47±10.83 years and 23 obese nondiabetic 
controls (8 males and 15 females; age, 53.04±11.33 years) were included in the study. Age, sex, and body mass index were similar 
in the 2 groups. Serum visfatin and fetuin-A levels were measured by enzyme-linked immunosorbent assay. HbA1c and urine al-
bumin levels were measured by high performance liquid chromatography and nephelometric method, respectively.
Results:  Serum levels of visfatin in patients with T2DM (4.03±2.44 ng/mL) were similar to the control group (3.65±3.02 ng/
mL). Serum fetuin-A levels were significantly lower in patients with T2DM than the controls (298.75±78.86 and 430.73±94.46 
µg/mL, respectively). HbA1c levels were significantly higher in the T2DM group compared with controls (7.33±1.32 and 5.44± 
0.84%, respectively). Correlations between visfatin, fetuin-A and HbA1c levels were not observed.
Conclusion:  The present study suggests fetuin-A may play a role in the pathogenesis of T2DM. 
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INTRODUCTION
Adipose tissue has been shown to secrete a variety of bioactive 
compounds into the circulation that can have profound effects 
on metabolism [1]. Visfatin is one of the bioactive compounds 
that influence insulin receptors by binding to a different place 
than insulin [2]. There are several studies having conflicting 
results regarding the correlation of visfatin with insulin. Some 
studies suggested visfatin may be correlated with insulin resis-
tance [3-5] and another study reported visfatin may be corre-
lated with insulin sensitivity [6]. Chen et al. [7] reported visfa-
tin is associated with abdominal obesity and type 2 diabetes 
mellitus (T2DM) in the Taiwanese population. Hammarstedt 
et al. [8] showed higher circulating visfatin levels as well as ad-
ipose tissue visfatin mRNA expression in T2DM compared to 
body mass index (BMI)-unmatched controls.
  Fetuin-A is a 60 kDa protein synthesized in hepatocytes. 
Fetuin-A binds to insulin receptors in adipose and muscular 
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tissue and inhibits insulin receptor tyrosine kinase activity as 
well as insulin receptor autophosphorylation in vivo and in vi-
tro [9]. Fetuin-A has been suggested to potentially cause insu-
lin resistance and/or metabolic syndrome [9]. In terms of 
treatment or prevention of insulin resistance, fetuin-A may be 
considered as a new therapeutic target [10].
  Even if visfatin and fetuin-A levels have been studied in 
T2DM patients [7-13], none of the studies included the rela-
tionship of these bioactive compounds to HbA1c and albu-
minuria. Therefore, the goal of the present study was to inves-
tigate the serum visfatin and fetuin-A levels and determine 
whether there were any serum visfatin and fetuin-A correla-
tions with hemoglobin A1c (HbA1c) and urine albumin levels 
in obese T2DM patients, as well as contributing to the clarifi-
cation of the role of visfatin and fetuin-A in glucose metabo-
lism.
METHODS
The present study was performed in Istanbul Okmeydani Ed-
ucational and Research Hospital Clinical Biochemistry Labo-
ratory with 40 T2DM and 23 healthy control subjects. The pa-
tients were followed up in diabetes outpatient clinics. BMI of 
all individuals were calculated. In both groups, subjects with a 
BMI ≥25 kg/m
2 were included. Attention was given to the 
similarity between control and T2DM patient groups in terms 
of BMI, age and gender. The study was approved by the ethics 
commitee of our hospital. All individuals were informed re-
garding the tests and their clinical meanings before the study 
and written consent was obtained from all study participants. 
  For all laboratory tests in both control and T2DM groups, 
from each patient 10 mL of blood was collected into a vacuum 
tube with gel and 3 mL collected into a tube with K3EDTA. In 
order to determine urine albumin levels, a 24 hour urine spec-
imen was collected into clean, dry plastic bottles. Patients were 
asked to avoid exercise at least 24 hours before specimen col-
lection.
  Thr blood collected in the tube with gel was centrifuged at 
2,000×g for 10 minutes after clot formation and the serum 
separated. Routine biochemical parameters, HbA1c and urine 
albumin level were measured the same day. Undiluted serum 
specimen was divided into 2 aliquots and stored at -80ºC for 3 
months for visfatin and fetuin-A measurements. Repetitive 
freezing and thawing were not performed.
  Glucose and urea were analyzed in an Olympus AU2700 
chemistry analyzer (Beckman Coulter Inc., Fullerton, CA, 
USA); total cholesterol (TC), creatinine, triglycerides (TG), 
high density lipoprotein cholesterol (HDL-C) and low density 
lipoprotein cholesterol (LDL-C) were analyzed in a Modular 
V2 chemistry analyzer (Roche Diagnostics, Mannheim, Ger-
many) by photometric method; HbA1c was analyzed in an 
ADAMS A1c HA-8160 analyzer (Arkray Inc., Kyoto, Japan) by 
high performance liquid chromatography (HPLC); urine al-
bumin was analyzed in a Delta Nephelometry analyzer (Rad-
im Diagnostics, Rome, Italy) by nephelometric method; visfa-
tin (Alpco Diagnostics, Salem, NH, USA) and fetuin-A (As-
sayMax Human alpha-2-HS-Glycoprotein-AHSG-ELISA Kit; 
Assaypro, St. Charles, MO, USA) were analyzed by the en-
zyme-linked immunosorbent assay (ELISA) method. 
Performance characterization
Intra-assay and inter-assay coefficients of variation for fetuin-
A and visfatin were 4.9% and 7.1%; 5.5% and 6.24%, respec-
tively. 
Data processing methods
Statistical analyses were performed by the statistical program 
SPSS for Windows, version 11.5 (SPSS Inc., Chicago, IL, USA). 
Jarque-Bera normality test was applied to data; P<0.05 indi-
cated that normal distribution was not achieved. Therefore, to 
test differences between groups, non-parametric (non-requir-
ing normal distribution) Mann-Whitney U test for 2 indepen-
dent groups were applied. Kendall’s tau_b correlation coeffi-
cient was used to evaluate correlations. 
RESULTS
The present study was performed on 63 individuals consisting 
of 40 T2DM patients and 23 healthy controls. Among the in-
dividuals, 44 (70%) were females and 19 (30%) were males. 
There were no significant differences between T2DM patient 
and control groups in terms of age, gender, and BMI (P>0.05) 
(Table 1).
  A statistically significant difference between groups in terms 
of fetuin-A was detected (P<0.05). When rank values were 
controlled in order to determine the source of difference, low-
er levels were detected in the T2DM patient group in compari-
son to the control group (P<0.01). HbA1c, glucose and urea 
were found in higher levels in the T2DM patient group when 
compared to control group (P<0.001, P<0.001, and P<0.05, 525
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respectively). There were no differences between T2DM pa-
tient and control groups in terms of creatinine, TC, TG, HDL-
C, LDL-C, and visfatin (P>0.05) (Table 1).
  In the second stage of the study, the correlation of fetuin-A, 
visfatin and HbA1c variables was analyzed. Since the data did 
not exhibit normal distribution, Kendall’s tau_b correlation 
coefficient was used. For the T2DM patient group, a signifi-
cant correlation was not observed between the parameters 
(P>0.05) (Table 2).
  In the control group, a weak, but significant correlation was 
observed only between the visfatin and HbA1c variables (r=
0.318, P<0.05) (Table 2). 
  In the T2DM patient group, when 2 subgroups (1 group 
having HbA1c ≥7% and poor metabolic control and the other 
group HbA1c <7% and good metabolic control) were com-
pared in terms of demographic and biochemical parameters, 
only glucose and HbA1c values manifested statistically signifi-
cant differences (P<0.01 and P<0.05, respectively) (Table 3).
  When the correlations between variables in the T2DM pa-
tient group were analyzed, microalbuminuria had a weak but 
significant negative correlation with DM duration, and a posi-
tive correlation with glucose; urea had a positive correlation 
Table 1.  Comparisons of demographic and laboratory data 
between T2DM patient and control groups 
Parameter
T2DM  
patient group, 
median±IQR
Control group, 
median±IQR
P value
Age, yr 54.50±19.00 55.04±18.00 0.637
Sex, M/F 11 (27%)/29 (73%) 8 (34%)/15 (66%) 0.547
BMI, kg/m
2 30.00±5.00 32.00±5.00 0.162
Glucose, mg/dL 154.50±47.75 93.00±15.00 <0.001
Urea, mg/dL 29.50±11.75 25.00±14.00 0.043
Creatinine, mg/dL 0.90±0.30 0.80±0.20 0.097
TC, mg/dL 188.50±58.00 196.82±39.00 0.350
TG, mg/dL 142.50±147.00 130.69±94.00 0.525
HDL-C, mg/dL 45.00±14.25 48.00±12.00 0.106
LDL-C, mg/dL 108.00±40.50 121.00±40.00 0.189
HbA1c, % 7.25±1.27 5.40±0.50 <0.001
Fetuin-A, µg/mL 298.50±93.50 391.00±162.00 <0.001
Visfatin , ng/mL 3.85±4.05 3.10±6.40 0.520
MU, mg/day 55.00±81.15 ND  
T2DM, type 2 diabetes mellitus; IQR, interquartile range; BMI, body 
mass index; TC, total cholesterol; TG, triglyceride; HDL-C, high den-
sity lipoprotein cholesterol; LDL-C, low density lipoprotein choles-
terol; HbA1c, hemoglobin A1c; MU, microalbuminuria; ND, not de-
termined. 
Table 3.  Comparisons of T2DM patients’ demographic and 
laboratory data between HbA1c ≥7% and HbA1c <7% sub-
groups
Parameter
T2DM patients 
with good meta-
bolic control 
(HbA1c <7%), 
median±IQR 
(n=15)
 T2DM patients 
with poor meta-
bolic control 
(HbA1c ≥7%), 
median± 
IQR (n=25)
P value
DM duration, yr 8.00±18.00 12.00±13.00 0.56
BMI 29.00±6.00 30.00±4.00 0.73
Glucose, mg/dL 128.00±50.00 173.00±52.50 <0.01
Urea, mg/dL 29.00±11.00 30.00±11.50 0.41
Creatinine, mg/dL 0.70±0.30 0.90±0.25 0.35
TC, mg/dL 194.00±46.00 185.00±56.00 0.96
TG, mg/dL 129.00±74.00 158.00±153.50 0.24
HDL-C, mg/dL 42.00±8.00 45.00±15.50 0.44
LDL-C, mg/dL 127.00±37.00 102.00±35.00 0.29
MU, mg/day 31.00±26.00 37.00±34.00 0.13
HbA1c, % 6.30±0.70 7.50±0.80 <0.05
Fetuin-A, µg/mL 301.00±112.50 292.00±94.00 0.75
Visfatin, ng/mL 4.00±4.35 3.60±4.30 0.63
T2DM, type 2 diabetes mellitus; HbA1c, hemoglobin A1c; IQR, in-
terquartile range; DM, diabetes mellitus; BMI, body mass index; TC, 
total cholesterol; TG, triglyceride; HDL-C, high density lipoprotein 
cholesterol; LDL-C, low density lipoprotein cholesterol; MU, micro-
albuminuria.
Table 2.  Correlations between HbA1c, fetuin-A, and visfatin levels in the control and T2DM patient groups
Parameter
 
T2DM patient group Control group
HbA1c Fetuin-A HbA1c Fetuin-A
r P  r P  r P  r P 
Visfatin, ng/mL 0.151 0.176 -0.094 0.395 0.318 0.040 0.028 0.853
Fetuin-A, µg/mL 0.048 0.666 - 0.054 0.729 - -
HbA1c, hemoglobin A1c; T2DM, type 2 diabetes mellitus.526
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with DM duration and creatinin, and a negative correlation 
with visfatin (Table 4). 
  The T2DM patient group was further divided into 2 sub-
groups having microalbuminuria (mg/day) ≥30 (n=24) and 
<30 (n=16). When the 2 groups were compared in terms of 
duration of DM, BMI, glucose, urea, creatinine, TC, TG, HDL-
C, LDL-C, HbA1c, visfatin, and fetuin-A parameters, there 
were no statistically significant differences between the 
groups. 
DISCUSSION
In the present study, demographic and anthropometric pa-
rameters such as age, gender, BMI, and serum levels of creati-
nine, TC, TG, HDL-C, LDL-C did not manifest statistically 
significant differences between the T2DM patient and control 
groups. Since both study groups had the same confounding 
factors for insulin sensitivity, an opportunity to exclude varia-
tions originating from these parameters existed. 
  HbA1c, glucose and urea levels were detected higher in the 
T2DM patient than control group. Elevation of HbA1c and 
glucose levels were compatible with DM. The mean microal-
buminuria levels of the T2DM patient group were >30 mg/day 
indicating the presence of microalbuminuria. Elevated serum 
urea and urine albumin levels indicated the existence of ne-
phropathy in the T2DM group. 
  In the present study, there were no differences between the 
T2DM patient and control groups in terms of visfatin levels. 
Fukuhara et al. [6] reported that visfatin is related to insulin 
sensitivity [6]. Chen et al. [7] evaluated plasma visfatin levels 
in 61 T2DM patients and 59 healthy controls with similarity in 
terms of gender and age. Visfatin levels were higher in T2DM 
patients and the authors stated visfatin can play a role in patho-
genesis of T2DM. Yilmaz et al. [11] evaluated visfatin and fe-
tuin-A levels in 85 T2DM patients having early stage diabetic 
nephropathy and 38 healthy controls; higher visfatin levels 
were observed in the T2DM patient group compared to the 
healthy control group. The visfatin result in the present study 
is in contradiction with Yilmaz et al. [11]. In the present study, 
smoking and alcohol drinking habits of the patients were not 
evaluated. Therefore, the T2DM patient group in the present 
study showed differences from Yilmaz et al. [11] whose patient 
group was composed of patients who had DM and had a new 
diagnosis of nephropathy, excluding patients with smoking 
and alcohol drinking habits. The reason for different visfatin 
levels in the T2DM patient group of the present study and 
Yilmaz’s group [11] may be due to differences in demographic 
characteristics and exclusion criteria.
  Dogru et al. [12] evaluated plasma visfatin levels in 22 T2DM 
patients who were newly diagnosed and did not receive treat-
ment, 22 individuals who had impaired glucose tolerance, and 
40 healthy individuals (control group) with similarity in terms 
of age, BMI and gender and detected higher visfatin levels in 
the diabetic group. The authors claimed hyperglycemia in-
Table 4.  Correlations between the parameters in the T2DM patient group
 
 
DM duration, 
yr
Fetuin-A,  
µg/mL
Visfatin,  
ng/mL
HbA1c,
 %
MU,
 mg/day
Urea,
 mg/dL
Creatinine, 
mg/dL
Glucose,  
mg/dL
r P r P r P r P r P r P r P r P
DM duration, 
yr
    -0.062 0.583 -0.194 0.084 0.057 0.615 -0.228 0.042 0.300 0.008 0.183 0.122 0.050 0.420
Fetuin-A, 
µg/mL
-0.062 0.583     -0.094 0.395 0.048 0.666 0.085 0.441 0.102 0.362 0.079 0.499  0.010  0.650
Visfatin,  
ng/mL
-0.194 0.084 -0.094 0.395     0.151 0.176 -0.084 0.448 -0.241 0.032 -0.053 0.652 0.120  0.270
HbA1c, % 0.057 0.615 0.048 0.666 0.151 0.176     0.073 0.513 0.054 0.632 0.183 0.120  0.040  0.523
MU,  
mg/day
-0.228 0.042 0.085 0.441 -0.084 0.448 0.073 0.513     0.156 0.164 0.156 0.183  0.279  0.012
Urea,  
mg/dL
0.300 0.008 0.102 0.362 -0.241 0.032 0.054 0.632 0.156 0.164     0.422 <0.001  0.017  0.879
Creatinine,  
mg/dL
0.183 0.122 0.079 0.499 -0.053 0.652 0.183 0.120 0.156 0.183 0.422 <0.001      0.100  0.360
T2DM, type 2 diabetes mellitus; DM, diabetes mellitus; HbA1c, hemoglobin A1c; MU, microalbuminuria.527
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creases plasma visfatin levels and this increase makes the im-
pairment in glucose tolerance more prominent. 
  Sandeep et al. [13] evaluated plasma visfatin levels in 150 
T2DM patients and 150 individuals having normal glucose 
tolerance, and observed higher visfatin levels in the diabetic 
group compared to the normal glucose tolerance group. 
  Hammarstedt et al. [8] showed higher circulating visfatin 
levels as well as adipose tissue visfatin mRNA expression in 
T2DM compared to BMI-unmatched controls. The difference 
between the BMIs in the 2 groups was a limitation of Ham-
marstedt et al.’s study.
  There are also several studies indicating no association be-
tween serum visfatin levels with insulin sensitivity or resis-
tance [4,8,14]. The visfatin results in the present study are com-
patible with these studies [4,8,14] and are not compatible with 
other studies [6,7,11-13]. Individuals in the present study’s 
T2DM patient group were treated for both diabetes and mi-
croalbuminuria and the treatments had several differences. 
The reason for finding no differences in terms of visfatin levels 
between groups may be due to interaction of visfatin with oth-
er drugs. 
  In the present study, lower fetuin-A levels were observed in 
the T2DM patient group compared to the control group. 
  Ix et al. [10] followed for 6 years 406 healthy and non-dia-
betic individuals between 70 and 79 years of age regarding dia-
betes status; T2DM developed in 135 individuals during the 
study period. The authors measured fetuin-A levels and ob-
served higher fetuin-A levels in individuals who developed di-
abetes and stated fetuin-A levels were correlated with develop-
ing diabetes in elder people, being independent of other indi-
cators of insulin resistance. The authors claimed that if further 
studies are performed in middle aged groups having the high-
est rate of diabetes incidence and if their results were con-
firmed, fetuin-A can offer an useful therapeutic target and can 
provide new insights for glucose metabolism in humans [10].
  Takata et al. [15] investigated the effect of high glucose level 
on the fetuin-A gene in human hepatoma cell line HepG2 and 
observed fetuin-A expression in the cells. The authors claimed 
that increase in expression of AHGS (fetuin-A) in the liver 
may be a reason for glucose toxicity in diabetic conditions. 
  Mori et al. [16] evaluated serum fetuin-A levels in 162 type 
2 diabetic and 160 non-diabetic individuals and did not find 
any difference between groups in terms of fetuin-A and any 
significant correlation between insulin resistance and fetuin-
A. The authors hypothesized the reason may be the presence 
of stronger determinants similar to protein modifications such 
as non-enzymatic glycation masking the effect of fetuin-A on 
insulin resistance and having excessive glucose toxicity under 
diabetic conditions or influence of pharmacologic treatment 
of diabetic individuals on fetuin-A levels. 
  In another study, Mori et al. [9] investigated the effects of 
insulin sensitizing treatment such as pioglitazone, metformin 
and aerobic exercise. The authors divided 27 T2DM individu-
als into 3 groups (10 pioglitazone, 9 using metformin for 6 
months, and 7 having a 3-month exercise program). After the 
treatment period, fetuin-A levels decreased significantly in the 
group using pioglitazone. Consequently, the authors stated 
that pioglitazone may partially regulate insulin resistance by 
decreasing fetuin-A levels. 
  Yilmaz et al. [11] divided patients into 2 groups in terms of 
proteinuria, <500 mg/day and ≥500 mg/day, and measured 
visfatin, fetuin-A, adiponectin and hsCRP levels. The authors 
observed significantly lower fetuin-A levels in the diabetic 
group and a negative correlation with proteinuria. Yilmaz et 
al. [11] expressed that a urinary loss of fetuin-A, which is a va-
soprotective protein, may contribute to increased cardiovas-
cular disease risk in these patients. 
  In the present study, fetuin-A levels in the T2DM group 
were lower compared to the control group which was compat-
ible with Yilmaz et al. [11] and not compatible with Ix et al. 
[10], Takata et al. [15], and Mori et al. [16]. 
  The authors of the present study measured urine albumin 
levels in the T2DM group. Microalbuminuria levels of the 
T2DM patient group were 55.07±81.15 mg/day (mean± 
standard deviation) and the mean was over the reference range. 
This result is an indicator of diabetic nephropathy developing 
in the T2DM patient group. Although serum fetuin-A levels 
were lower overall in the T2DM group compared to control 
group, stating that fetuin-A levels were not different according 
to the presence of proteinuria was difficult because of the small 
number of subjects and this was a limitation of the present 
study. 
  HbA1c, which is positively correlated with glucose levels 
and increased in T2DM, has a role in development of micro-
vascular complications. Correlation between HbA1c and vis-
fatin or fetuin-A in both study groups was not observed. A 
possible reason is that the result may be due to the effect of drug 
treatments masking a correlation or visfatin and fetuin-A may 
have roles in different mechanisms in T2DM pathogenesis. 
  After dividing groups in terms of HbA1c and microalbu-528
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minuria, between groups of HbA1c ≥7% and HbA1c <7%, 
statistically significant differences in terms of duration of DM, 
BMI, urea, creatinine, TC, HDL-C, LDL-C, microalbumin-
uria, visfatin, and fetuin-A levels could not be found. 
  Similarly, there was no significant difference between the 
T2DM group having microalbuminuria (≥30 mg/day) and 
the normoalbuminuria group (<30 mg/day) in terms of dura-
tion of DM, BMI, glucose, urea, creatinine, TC, HDL-C, LDL-
C, HbA1c, visfatin, and fetuin-A levels. 
  Consequently, low serum levels of fetuin-A in the T2DM 
patient group may suggest fetuin-A is a factor having a role in 
T2DM pathogenesis, although neither visfatin nor fetuin-A 
were correlated with HbA1c and albuminuria levels in patients 
with T2DM.
CONFLICTS OF INTEREST
No potential conflict of interest relevant to this article was re-
ported. 
REFERENCES
1. Guerre-Millo M. Adipose tissue hormones. J Endocrinol In-
vest 2002;25:855-61. 
2.  Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I. Cloning 
and characterization of the cDNA encoding a novel human pre-
B-cell colony-enhancing factor. Mol Cell Biol 1994;14:1431-7. 
3.  Ognjanovic S, Bao S, Yamamoto SY, Garibay-Tupas J, Samal B, 
Bryant-Greenwood GD. Genomic organization of the gene 
coding for human pre-B-cell colony enhancing factor and ex-
pression in human fetal membranes. J Mol Endocrinol 2001; 
26:107-17. 
4.  Berndt J, Kloting N, Kralisch S, Kovacs P, Fasshauer M, Schon 
MR, Stumvoll M, Bluher M. Plasma visfatin concentrations 
and fat depot-specific mRNA expression in humans. Diabetes 
2005;54:2911-6. 
5.  Haider DG, Schaller G, Kapiotis S, Maier C, Luger A, Wolzt M. 
The release of the adipocytokine visfatin is regulated by glucose 
and insulin. Diabetologia 2006;49:1909-14. 
6.  Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, 
Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami 
H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, 
Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hira-
matsu R, Matsuzawa Y, Shimomura I. Visfatin: a protein se-
creted by visceral fat that mimics the effects of insulin. Science 
2005;307:426-30. 
7.  Chen MP, Chung FM, Chang DM, Tsai JC, Huang HF, Shin SJ, 
Lee YJ. Elevated plasma level of visfatin/pre-B cell colony-en-
hancing factor in patients with type 2 diabetes mellitus. J Clin 
Endocrinol Metab 2006;91:295-9. 
8.  Hammarstedt A, Pihlajamaki J, Rotter Sopasakis V, Gogg S, 
Jansson PA, Laakso M, Smith U. Visfatin is an adipokine, but it 
is not regulated by thiazolidinediones. J Clin Endocrinol Metab 
2006;91:1181-4. 
9.  Mori K, Emoto M, Araki T, Yokoyama H, Lee E, Teramura M, 
Koyama H, Shoji T, Inaba M, Nishizawa Y. Effects of piogli-
tazone on serum fetuin-A levels in patients with type 2 diabe-
tes mellitus. Metabolism 2008;57:1248-52.
10.  Ix JH, Wassel CL, Kanaya AM, Vittinghoff E, Johnson KC, 
Koster A, Cauley JA, Harris TB, Cummings SR, Shlipak MG. 
Health ABC Study. Fetuin-A and incident diabetes mellitus in 
older persons. JAMA 2008;300:182-8. 
11.  Yilmaz MI, Saglam M, Qureshi AR, Carrero JJ, Caglar K, Ey-
ileten T, Sonmez A, Cakir E, Oguz Y, Vural A, Yenicesu M, 
Stenvinkel P, Lindholm B, Axelsson J. Endothelial dysfunction 
in type-2 diabetics with early diabetic nephropathy is associat-
ed with low circulating adiponectin. Nephrol Dial Transplant 
2008;23:1621-7. 
12.  Dogru T, Sonmez A, Tasci I, Bozoglu E, Yilmaz MI, Genc H, 
Erdem G, Gok M, Bingol N, Kilic S, Ozgurtas T, Bingol S. Plas-
ma visfatin levels in patients with newly diagnosed and un-
treated type 2 diabetes mellitus and impaired glucose tolerance. 
Diabetes Res Clin Pract 2007;76:24-9. 
13.  Sandeep S, Velmurugan K, Deepa R, Mohan V. Serum visfatin 
in relation to visceral fat, obesity, and type 2 diabetes mellitus 
in Asian Indians. Metabolism 2007;56:565-70. 
14.  Krzyzanowska K, Krugluger W, Mittermayer F, Rahman R, 
Haider D, Shnawa N, Schernthaner G. Increased visfatin con-
centrations in women with gestational diabetes mellitus. Clin 
Sci (Lond) 2006;110:605-9. 
15.  Takata H, Ikeda Y, Suehiro T, Ishibashi A, Inoue M, Kumon Y, 
Terada Y. High glucose induces transactivation of the alpha2-
HS glycoprotein gene through the ERK1/2 signaling pathway. 
J Atheroscler Thromb 2009;16:448-56. 
16.  Mori K, Emoto M, Yokoyama H, Araki T, Teramura M, Koya-
ma H, Shoji T, Inaba M, Nishizawa Y. Association of serum fe-
tuin-A with insulin resistance in type 2 diabetic and nondia-
betic subjects. Diabetes Care 2006;29:468.